In theory, the biotech sector has plenty going for it from an investment perspective given that companies are aiming to develop drugs that are badly needed by people all around the world. However, it is a volatile part of the market, as the past couple of years have proven. Joining Kyle to explain why biotech has been out of favour, and making the case for why better times are ahead, is Rod Wong, founder and chief investment officer at RTW Investments, the investment manager of RTW Biotech Opportunities (LSE:RTW).
Please continue to provide your suggestions on questions you want answered on OTM@ii.co.uk.
On The Money is an interactive investor (ii) podcast. For more investment news and ideas, visit https://www.ii.co.uk/stock-market-news.
Kyle Caldwell is collectives editor at interactive investor.
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.